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Abstract
Introduction: Primary hyperparathyroidism (PHPT) is an increasingly common endocrine disorder. Most patients with PHPT do 
not have disease-specific symptoms. The management of these patients has been widely debated. Recent studies have shown the 
importance of following up asymptomatic patients in order to reduce co-morbidity. However, there are conflicting opinions as to 
medical management. 
The aim of our study was to compare the outcome of PHPT patients on antiresorptive therapy vs. observation only. 
Material and methods: We longitudinally evaluated 157 PHPT patients (126 females) aged 22–90 years. Patients who did not undergo 
surgery were divided into two groups: those on anti-resorptive therapy (N = 52), and those without any treatment (N = 37). Patients 
who were disease-free after surgery (N = 50) served as controls. 
Results: The values of serum calcium (S-Ca), parathyroid hormone (PTH) and indices of bone metabolism did not differ significantly 
among the three groups of subjects. No differences in 25(OH)-vitamin D levels were noted. Bone mineral density (BMD) was not signifi-
cantly different at the spinal level. Finally, we found no evidence of an effect of medical treatment on quality of life (QoL). However, QoL 
significantly improved in the surgery group after parathyroidectomy (PTX). 
Conclusions: This study provided up-to-date information in terms of biochemical progression on the natural history of PHPT patients. 
No significant differences emerged between anti-resorptive therapy and observation only. It is not yet possible to assess the effect of 
pharmacological treatments on QoL in statistical terms. (Endokrynol Pol 2014; 65 (6): 456–463)
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Streszczenie
Wstęp: Pierwotna nadczynność przytarczyc (PHPT) jest coraz częściej spotykanym zaburzeniem endokrynologicznym. Większość 
dotkniętych nim pacjentów nie ma szczególnych objawów podmiotowych, a metody leczenia schorzenia pozostają przedmiotem 
dyskusji. Najnowsze publikacje wskazują na konieczność obserwowania pacjentów bezobjawowych, co ma na celu zmniejszenie 
zapadalności na schorzenia współistniejące. Opinie na temat leczenia farmakologicznego są jednak podzielone. Celem niniejszego 
badania było porównanie przebiegu PHPT u pacjentów przyjmujących leki zmniejszające resorpcję kości i u pacjentów poddanych 
jedynie obserwacji. 
Materiał i metody: Przeanalizowano dane 157 pacjentów (w tym 126 kobiet) w wieku 22–90 lat chorujących na PHPT. Pacjentów 
nieleczonych chirurgicznie podzielono na dwie grupy: grupa leczonych preparatami hamującymi resorpcję kości (n = 52) i grupa 
nieleczona farmakologicznie (n = 37). W grupie kontrolnej znaleźli się pacjenci bez objawów choroby po zabiegu chirurgicznym 
(n = 50).
Wyniki: Stężenia wapnia w surowicy (S-Ca), aktywność parathormonu (PTH) i wskaźniki metabolizmu kostnego nie różniły się istotnie 
w trzech badanych grupach pacjentów. Nie stwierdzono różnic pod względem stężenia witaminy 25-OH-D (hydroksycholekalcyferolu). 
Gęstość mineralna kości (BMD) w obrębie kręgosłupa nie różniła się istotnie pomiędzy grupami. Nie stwierdzono też wpływu farmakoterapii 
na jakość życia (QoL). Odnotowano jednak, że QoL poprawiła się istotnie po zabiegu paratyreoidektomii (PTX) w grupie operowanej. 
Wnioski: Niniejsze badanie przynosi informacje na temat naturalnego przebiegu i zmian biochemicznych u chorych na PHPT. Nie stwier-
dzono istotnych różnic pomiędzy grupą pacjentów leczonych preparatami hamującymi resorpcję kości a pacjentami nieleczonymi. Nie 
można jednak było ocenić statystycznie wpływu leczenia farmakologicznego na QoL. (Endokrynol Pol 2014; 65 (6): 456–463)
Słowa kluczowe: pierwotna nadczyność przytarczyc; PHPT; leczenie farmakologiczne; obserwacja kliniczna; badanie w układzie podłużnym; 
usunięcie przytarczyc
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N = 11, clodronate 100 mg/week N = 6); 37 were not 
on any treatment (untreated group); and 50 were 
disease-free after surgery (surgery group). When 
required, patients underwent supplementation with 
vitamin D (< 25mmol/L = 2,000 U/day, 25–50 mmol/L 
= 1,000 U/day, 50–75 mmol/L = 800 U/day, as reported 
in the guidelines SIOMMMS).
Written informed consent was obtained from all 
participants.
Study design
Evaluation was based on clinical examination, neck 
ultrasonography, bone mineral density (BMD) and 
blood tests. S-Ca and PTH levels were recorded 
on each occasion. Serum phosphorus, 25hydroxy-
vitaminD (25OHD) and 1.25dihydroxy-vitaminD 
(1.25OHD), creatinine, total and bone-specific alkaline-
phosphatase (ALP), urinary cross-links and osteocalcin 
were measured annually. Finally, an Italian ad hoc 
parathyroid questionnaire (PQ) was administered to all 
patients, to evaluate their QoL. On entry to the study, 
a semi-structured clinical interview was conducted by 
a psychiatrist. All subjects were then asked to complete 
the Italian version of the self-rated Kellner symptom 
questionnaire (KSQ) [8].
Laboratory evaluations
PTH was analysed by means of two chemiluminescence 
immunoassays (2007-2008: Immunolite2000, Diagnostic 
Products, San Juan Capistrano, CA, USA; from 2009: 
LIASON N-tactPTH, DIASorin, Saluggia, Italy). Re-
producibility of the data yielded by the two methods 
was excellent. The reference range (r.r.) is 15–65 ng/L or 
< 36.8 ng/L. Creatinine (r.r., 44.0–115.0 μmol/L), S-Ca 
(2.1–2.7 mmol/L), phosphorus (0.8–1.4 mmol/L), and 
ALP (98.0–280.0 U/L) levels were determined by means 
of fully automatic equipment (ModularP800, Roche 
Diagnostics). Evaluation of 25OHD was performed 
by means of a chemiluminescence method (LIAISON, 
DIASorin). A range of 75–250 nmol/L was considered 
indicative of adequate vitamin D intake. Evaluation 
of 1.25OHD (r.r. 47.6–150 pmol/L) was performed by 
radioimmunoassay (Immunodiagnostic Systems). Os-
teocalcin (r.r. 0.5–7.0 ng/mL) was measured by means 
of an immunochemiluminescence method (Nichols). 
Urinary cross-links (expressed as the molar ratio of 
creatinine) were measured by high-performance liquid 
chromatography (BioRad, Milan, Italy).
Imaging
Colour-Doppler neck ultrasonography (AU5Idea and 
MyLabFive; Esaote, Genoa, Italy) was performed by 
means of a device equipped with a linear 7.5–10 MHz 
probe. When indicated, fine-needle aspiration was 
Introduction
Primary hyperparathyroidism (PHPT) is a disorder 
characterised by inappropriately high secretion of 
parathyroid hormone (PTH). PHPT has become 
a common disease, with an estimated prevalence of 1% 
of the general population and 3% in postmenopausal 
women [1], and an increasing incidence over the last 
few decades. 
PHPT is usually the result of a single over-active 
parathyroid gland as a result of adenoma, hyperplasia 
or cancer [2]. The clinical presentation has changed over 
the years: today, 80–85% of cases are asymptomatic [3]. 
A National Institutes of Health consensus panel has 
recognised two forms of the disease: asymptomatic and 
symptomatic [4]. The diagnosis is based on the clinical 
and objective picture, evaluation of serum calcium 
(S-Ca) and PTH. Preoperative localisation studies are 
required.
Therapy may involve medical or surgical treatment, 
and many guidelines have been proposed over the 
years. Although parathyroidectomy (PTX) is regarded 
as the treatment of choice for patients with symptomatic 
hypercalcaemia or evidence of target organ damage [5], 
conservative management has been favoured in asymp-
tomatic patients. In addition, in some cases surgery fails, 
in some it is contraindicated, and in others it is refused 
[6]. At the most recent International Workshop [7], the 
guidelines pointed out that there was no data to support 
the medical treatment of patients with mild PHPT. In 
general, it is recommended that patients who do not 
meet surgical criteria [7] be monitored closely. How-
ever, the validity of medical treatment is unanimously 
recognised. The prognosis of PHPT patients depends 
on the time-line of the diagnosis.
The aims of our five-year study were: 1) to evaluate 
patients with PHPT during the course of different types 
of treatment; and 2) to evaluate quality of life (QoL) in 




We longitudinally evaluated all patients (aged 22–90 
years) with a history of PHPT in our endocrine unit 
from 2007–2011. Over the years, the number of pa-
tients progressively increased. Patients (N = 18) on 
cinacalcet were excluded from the study owing to 
their small number. The remaining study popula-
tion was divided into three groups: 52 patients were 
on anti-resorptive therapy (bisphosphonate-treated 
group: alendronate 70 mg/week N = 22, risedronate 
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performed and PTH was evaluated in fine-needle wash-
ing in order to locate hyperfunctioning parathyroid 
tissue [9, 10]. BMD (gr/cm2) in the lumbar spine and 
total hip was measured in the antero-posterior direc-
tion by means of a dual-energy X-ray absorptiometry 
technique (DXA) using Hologic instruments (QDR1500 
and DQR4500, Bedford, MA). BMD was expressed as 
a T-score. The so-called standard deviation (SD) scores 
were calculated from the following equation: T-score 
= (BMD measured–BMD of a sex- and age-matched 
population)/SD. DXA was also evaluated at the baseline 
and each year.
Survey measurements
The ad hoc PQ was prepared as a simplified version of 
the medical outcome study 36-item short-form survey 
(SF-36), which is a well-validated measure of general 
health status [11]. PQ comprised 39 questions, grouped 
into eight items designed to explore changes in general 
health perception, physical function, presence/absence 
of physical pain, social relations, mental health, osteoar-
ticular pain, tiredness or vitality, and specific symptoms. 
PQ was scored by assigning one point for each negative 
reply (no physical or mental changes) and two points 
for each positive reply (physical or mental changes). 
The total score ranges from 39-78 [12].
The self-rated KSQ had already been used by us 
[12] and others [13] in similar studies. KSQ comprises 
eight subscales. The items anxiety, depression, somatisa-
tion and hostility evaluate the degree of psychological 
discomfort or lack of well-being on a numerical scale 
ranging from 0–23 for each item. The higher the score, 
the lower the QoL.
Statistical analysis
In accordance with the classification of the WHO, osteo-
porosis was defined as a T-score < –2.5 and osteopenia 
as a T-score between –2.5 and –1.0. Data was analysed 
by means of GraphPad Prism for Windows (Version4.0; 
GraphPad Software, San Diego, CA, USA). All values 
are expressed as mean ± standard error of mean (SEM) 
unless indicated otherwise. To evaluate changes in 
experimental parameters during the five-year study, 
the non-parametric Kruskal-Wallis analysis of variance 
(ANOVA), followed by Dunn’s Multiple Comparison 
test, was used. To compare absolute and percentage 
data, Mann-Whitney and Chi-square tests were used. 
Correlation analyses between variables were carried 
out by means of the Spearman correlation. Data below 
the functional sensitivity or above the standard curve 
of the assays were analysed for statistical purposes by 
using the functional sensitivity value or the maximal 




In total, 157 patients with PHPT were followed up. 
Inter-group comparison by means of ANOVA revealed 
no significant differences in age (65.2 ± 14.0 years ± SD; 
P = 0.07), female:male ratio, or smoking (Appendix I). 
In the study population, mean body mass index (BMI) 
was 28.8 ± 5.2 kg/m2. Similar numbers of patients were 
overweight (BMI = 25–30 kg/m2) in the three study 
groups (patients with/without therapy, N = 38, 44%, 
and surgery group, N = 26, 52%). Eighty-three pa-
tients underwent one or more PTX. Histology revealed 
parathyroid adenoma in most cases (N = 66; 79.5%) or 
hyperplasia (N = 7; 8.4%), and parathyroid carcinomas 
in three patients; histopathology data from the remain-
ing (N = 10) patients could not be retrieved. About 50% 
of no-PTX patients (N = 37) were already symptomatic 
at the time of diagnosis, while 48% (N = 40) of those 
who had undergone surgery were symptomatic. At the 
time of diagnosis, 83 patients were symptomatic for 
kidney stones (N = 37), bone and joint pains (N = 24), 
osteoporosis (N = 23), pathological fractures (N = 5), 
and pancreatitis (N = 2). 
Laboratory data
The untreated group and the bisphosphonate-treated 
group showed similar reductions in S-Ca and PTH con-
centrations over the five-year follow-up. However, both 
groups differed significantly from the surgery group: 
PTH levels (P = 0.05) in the untreated group (P = 0.01) 
were significantly higher than in the surgery group; 
S-Ca levels (P = 0.0001) were lower in the surgery group 
than in the other two groups (Fig. 1).
In all PTX patients, there was a significant difference 
(P < 0.001) between pre-surgical and post-surgical S-Ca 
levels. However, while PTH levels remained essentially 
unchanged in the bisphosphonate-treated group before 
and after the initiation of drug therapy, serum levels of the 
hormone were significantly (P < 0.001) reduced after PTX.
Over the five-year study period, a significant reduc-
tion in PTH levels was seen only in the surgery group 
(P < 0.01); in the bisphosphonate-treated group, PTH 
levels tended to remain stable. A slight, non-significant 
increase in PTH levels was found in the untreated 
group. Similarly, S-Ca levels showed a significant reduc-
tion only in the surgery group (P < 0.05).
On final evaluation, other biochemical indices did 
not differ significantly among the three groups. Finally, 
48 (28.9%) patients showed Vitamin D deficiency (VDD) 
(25OHD < 50 nmol/L). These subjects received replace-
ment treatment with cholecalciferol (bisphosphonate-
treated group N = 33, mean dose 822.5 ± 158.6 U/day; 
surgery group N = 27, mean dose 737.5 ± 181.3 U/
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Table I. Clinical, biochemical and instrumental parameters in all groups of patients on initial evaluation and on last follow-
up evaluation (5 years). Data are expressed as mean ± SD unless otherwise specified
Tabela I. Kliniczne, biochemiczne i instrumentalne parametry we wszystkich grupach chorych podczas wstępnej oceny 
i ostatniej kontroli (5 lat). Dane wyrażono jako średnie ± SD, jeśli nie określono inaczej
Parameter Surgery-group Bisphosphonate-treated group Untreated-group
Initial Final Initial Final Initial Final
Number of patients 30 50 22 52 12 37
Female/male 21/9 31/19 19/3 40/12 10/2 31/6
Age (mean years) 61.5 ± 12.3 62.2 ± 1.9 71.7 ± 9.2 68.3 ± 1.6 62.1 ± 17.5 63.2 ± 1.9
BMI [kg/m2] 27.3 ± 4.3 27.4 ± 5.4 25.9 ± 4.3 26.2 ± 4.8 25.6 ± 5.5 26.2 ± 2.6
Smoking (%) 25 16 8 7 0 5
Time since diagnosis (years) 4.1 ± 5.8 7.0 ± 5.9 2.7 ± 3.0 5.4 ± 4.0 3.2 ± 4.9 5.6 ± 5.3
Creatinine [μmol/L] 79.6 ± 17.7 79 ± 18 61.9 ± 17.7 88 ± 35 70.7 ± 17.7 79 ± 9
S-Ca [mmol/L] 2.4 ± 0.7 2.4 ± 0.0 2.5 ± 0.2 2.5 ± 0.2 2.4 ± 0.2 2.6 ± 0.2
PTH [ng/L] 158.9 ± 29.1 76.1 ± 9.3 204.6±56.9 112.7 ± 111.7 109.9 ± 74.4 152.5 ± 26.3
Total ALP [U/L] 180.8 ± 61.5 144.0 ± 42.0 206.6 ± 56.4 158.3 ± 58.5 173.2 ± 54.0 185.2 ± 73.4
25OHD [nmol/L] 43.7 ± 24.2 64.2 ± 27.2 39.0 ± 20.2 50.2 ± 22.7 48 ± 24.7 40.7 ± 25.2
1.25OHD [pmol/L] 224.0 ± 115.9 255.2 ± 110.9 291.4 ± 151.5 278.3 ± 144.8 299.5 ± 102.4 311.0 ± 130.3
Lumbar spine (T-score) –1.99 ± 0.9 –1.75 ± 1.2 –2.08 ± 1.4 –2.18 ± 1.7 –1.80 ± 1.6 –1.54 ± 1.2
Total femur (T-score) –1.33 ± 0.8 –1.50 ± 0.3 –1.88 ± 0.9 –0.19 ± 1.8 –1.98 ± 1.2 –2.96 ± 0.9
Ultrasound TX 30% (N = 9) 36% (N = 18) 9.1% (N = 2) 13.5% (N = 7) 8.3% (N = 1) 8.1% (N = 3)
UNG/MNG 30% (N = 9) 42% (N = 21) 63.6% (N = 14) 53.8% (N = 28) 41.7% (N = 5) 46% (N = 17)
Normal ultrasound pattern 40% (N = 12) 22% (N = 11) 13.6% (N = 3) 21.2% (N = 11) 41.7% (N = 5) 29.7% (N = 11)
Parathyroid pathological – – 13.6% (N = 3) 11.5% (N = 6) 8.3% (N = 1) 16.2% (N = 6)
SD — standard deviation; BMI — body mass index; S-Ca — serum calcium; PTH — parathyroid hormone; ALP — alkaline phosphatase; 25OHD — 25-hydroxy-
vitamin D; 1,25OHD — 1.25dihydroxy-vitamin D; Tx — thyroidectomy; UNG — uninodular goitre; MNG — multinodular goitre; NS — not significant
Figure 1. PTH and S-Ca levels in the surgery group (subjects deemed disease-free after surgery, N = 50), untreated group (patients without 
medical therapy or surgery, N = 37), and bisphosphonate-treated group (patients on anti-resorptive treatment with bisphosphonates, N 
= 52). PTH displayed a significant difference (ANOVA P<0.05) between patients deemed disease-free after surgery and those without 
any therapy (A); regarding S-Ca, significant differences (ANOVA P = 0.001) emerged between patients deemed disease-free after 
surgery and those without therapy (A) and between patients deemed disease-free after surgery and those on bisphosphonate therapy (B)
Rycina 1. Aktywność PTH i stężenie wapnia w surowicy (S-Ca) w grupie operowanej (pacjenci bez objawów choroby po zabiegu 
operacyjnym, n = 50), w grupie nieleczonej (pacjenci nieleczeni farmakologicznie ani operacyjnie, n = 37) i w grupie leczonej 
bisfosfonianami (pacjencji leczeni bisfosfonianami w celu hamowania resoprcji kości, n = 52). Stwierdzono istotną różnicę aktywności 
PTH (ANOVA p < 0,05) pomiędzy pacjentami bez objawów choroby po zabiegu operacyjnym a pacjentami nieleczonymi w ogóle (A). 
Istotne różnice pod względem S-Ca (ANOVA p = 0,001) stwierdzono pomiędzy pacjentami bezobjawowymi po zabiegu chirurgicznym 
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day; untreated group N = 16, mean dose 896.1 ± 296.1 
U/day). Only the surgery group showed significantly 
lower 1.25OHD levels than the untreated group 
(P = 0.001). All data from the first and last observation 
periods is set out in the Appendix I. 
Instrumental data
Each year, ultrasonography was used to search for any 
sites of parathyroid tissue (Table I). 
BMD at the spinal level was not significantly dif-
ferent among the three groups of subjects (P = 0.1). 
T-scores were mildly, but not significantly, increased 
in the lumbar spine and unchanged at the femur level 
five years after observation or therapy. 
Quality of life
No significant differences in QoL scores emerged among 
the three groups of subjects (score: bisphosphonate-treat-
ed group 60.3 ± 8.9; untreated group 53.7 ± 17.9; surgery 
group 48.0 ± 6.7; ANOVA, P = 0.06). In the surgery 
group, however, QoL improved significantly after PTX 
(Wilcoxon, P = 0.05) (Fig. 2). Among PTX patients, 76% 
were satisfied with their PTX. 
In semi-structured interviews of 28 subjects (21 females/ 
/seven males, age 63.4 ± 15.7 years), the psychiatric 
evaluation performed did not detect any improve-
ment in psychopathology. In the majority of cases in 
which psychopathology was present, this was minor 
(anxiety, anxiety-depression, reactive depression); it 
was major in four (3%) patients (N = 1 potomania or 
psychogenic polydipsia; N = 1 panic attacks, N = 2 
major depression). Concomitant psychopathological 
events proved to be more frequent in women (males 
N = 2, females N = 14). The overall scores of the items 
on the self-rated KSQ were: anxiety 7.7 ± 3.5, depres-
sion 7.2 ± 5.3, somatisation 9.9 ± 6.1, and hostility 
4.9 ± 4.8. The correlations between age and KSQ 
scores, and between PTH and KSQ scores, were not 
statistically significant, nor was the correlation be-
tween KSQ and the duration (in months) of disease. 
No significant difference in KSQ scores emerged 
between females and males.
Discussion
Epidemiological considerations
The mean age of PTX patients was lower than that of the 
other groups. This is compatible with the fact that older 
people tend to have more co-morbidities (contraindica-
tions for surgery) and with the guidelines [7], which 
state that operable patients should be < 50 years old.
In our study, as in numerous epidemiological 
studies [10], PHPT was seen to be more frequent 
in females (N = 126, 77%) than in males (23%). Ad-
enomas accounted for the majority of cases. These 
findings reflect the normal histological distribution 
of PHPT, which is supported by a solitary adenoma 
in 85–90% of cases [14].
BMI was higher in PTX patients. The reason for this 
is unclear. Finally, although smoking is a risk factor 
for osteoporosis, there was no significant difference 
between the number of smokers/past-smokers and 
non-smokers in our study.
Figure 3. Distribution of prognoses in PHPT patients who 
underwent surgery. Both S-Ca and PTH concentrations 
normalised postoperatively in only 50.6%. In patients who 
underwent surgery, the clinical course and S-Ca levels prompted 
us to define the 8% of patients with hypercalcemia as ‘not cured’. 
In many patients (41.4%), S-Ca reverted to the normal range, 
while serum PTH concentration remained elevated
Rycina 3. Rokowanie u pacjentów chorych na PHPT po leczeniu 
chirurgicznym. Stężenie S-Ca i aktywność PTH uległy normalizacji 
po usunięciu przytarczyc tylko u 50,6% operowanych. Przebieg 
kliniczny i wartości stężeń S-Ca w tej grupie skłoniły autorów 
do stwierdzenia, że 8% pacjentów mających nadmierne stężenie 
wapnia w surowicy nie zostało wyleczonych (“not cured”). U wielu 
operowanych osób (41,4%), wartości S-Ca uległy normalizacji, 
natomiast aktywność PTH w surowicy pozostała zwiększona
Figure 2. Evaluation of pre- and post-surgery QoL by means of 
SF-36 scores in the three groups of subjects studied. A statistically 
significant difference was seen only in the surgery group (patients 
deemed disease-free after surgery)
Rycina 2. Badanie jakości życia (QoL) przy użyciu kwestionariusza 
SF-36 przed i po zabiegu operacyjnym w trzech grupach 
pacjentów. Statystycznie znamienną różnicę odnotowano tylko 
w grupie operowanej (pacjenci bez objawów choroby po zabiegu 
chirurgicznym)
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In the PTX patients, in agreement with previous evi-
dence [15], we recorded a high surgical success rate. 
However, in many patients, PTH concentration re-
mained elevated (Fig. 3); these findings are in line with 
those of the literature, although this is usually only seen 
in 20% of patients or less. It is also possible that some 
of these patients may have been suffering from VDD: 
vitamin D supplementation after PTX can reduce the 
incidence of increased PTH. In our series, the untreated 
patients had higher than average S-Ca values over time, 
while in the majority of our patients PTH remained 
stable or decreased over the five-year follow-up. As 
previously demonstrated [6], bisphosphonates do not 
normalise the levels of S-Ca and PTH. Likewise, in our 
series, all indices of bone metabolism differed only 
slightly in the bisphosphonate-treated group. Bispho-
sphonates are known to be effective in reducing bone 
turnover in PHPT patients [16]. However, we did not 
detect a significant difference in BMD in the subgroup 
treated. More recent data suggests that patients who 
have normal S-Ca levels after PTX, but elevated PTH, 
show no improvement in BMD comparatively [17]. This 
could explain why patients in all three groups displayed 
the same BMD changes.
Thus, medical management is a helpful alternative 
to PTX in patients for whom surgery is contraindicated 
or refused and in those patients with PHPT that relapses 
after surgery. Medical treatment is based on the use of 
bisphosphonates, oestrogens, modulators of oestrogen 
receptors and calciomimetics [18]. Antiresorptive ther-
apy may be an effective therapeutic approach in those 
patients with low BMD, in order to prevent further bone 
loss and to reduce the risk of fracture [19]. Moreover, 
a recent meta-analysis concluded that the effects of 
PTX and bisphosphonates were similar in mild PHPT 
[20]. Furthermore, PHPT patients have slightly lower 
25OHD levels than controls, despite supplementation. 
Indeed, PTH induces renal conversion of 25OHD to 
1.25OHD; integration may therefore require higher 
doses than in healthy subjects. 
However, we recommend vitamin D substitution 
before a final decision on treatment is made. Evidence 
that treatment with vitamin D reduces PTH levels and 
bone turnover in mild PHPT has been provided by case 
studies and uncontrolled/controlled cohort studies.
Quality of life
The clinical presentation of mild PHPT may include 
non-specific symptoms [21] that may affect QoL. In 
recent years, interest in QoL has grown in some endo-
crinological fields. Randomised studies have indicated 
beneficial effects of surgery on QoL, as surveyed by 
the SF-36; however, these effects have been minor and 
inconsistent, and the potential placebo effect of the 
surgery can never be ruled out [22]. One obstacle to 
evaluating illness perception in patients with PHPT is 
the current lack of developed questionnaires.
With regard to the outcome of PHPT patients, it has 
not been specified that ad hoc SF-36 and Hamilton tests 
should be administrated before and after PTX. Our ad 
hoc PQ had been prepared to measure general health 
status and specific symptoms of PHPT.
Our data shows that persistence of the disease was 
variable in the different groups. However, we noted 
that QoL only improved in the surgery group. Indeed, 
over five years, we documented an improvement in 
somatic and psychological symptoms related to the 
presence of disease. 
Limitations
Several limitations of our study have to be carefully 
considered, the first being the number of patients, 
which was somewhat lower than in other studies in 
the literature. However, over the years, the number of 
patients progressively increased and follow-up has now 
reached five years.
A second major limitation is related to the difficulty 
of randomising patients, as several types of treatment 
overlapped in the same subjects.
From a technological point of view, BMD was com-
pared at the spine. Although the wrist is the first site 
of osteoporosis in PHPT, wrist assessment was rarely 
performed in most patients.
Conclusions
This study provided up-to-date information in terms of 
biochemical progression on the natural history of PHPT 
patients. No significant differences emerged between 
anti-resorptive therapy and observation only. It is not 
yet possible to assess the effect of pharmacological 
treatments on QoL in statistical terms, although QoL 
appeared to worsen in our bisphosphonate-treated 
patients. However, the number of medically treated 
PHPT patients is increasing as a result of the review of 
surgical indications, the increased incidence of diagno-
ses in asymptomatic patients, and the development of 
new drug therapies.
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First name and Surname ...
Date...
Questionnaire for patients with hyperparathyroidism 
For the evaluation of the parameters:
1. General health perception
2. Physical function




7. Tiredness or vitality
8. Specific symptoms
Answer each of the following questions by marking your choice with a cross.
1. General health perception
 — Height loss Yes No
 — Sight impairment Yes No
 — Malaise Yes No
2. Physical function
 — Difficulty moving Yes No
 — Apathy Yes No
 — Tiredness Yes No
3. Various disorders
 — High blood pressure Yes No
 — Heartburn Yes No
 — Abdominal pain Yes No
 — Excessive thirst/urination Yes No
 — Weight loss Yes No
463












 — Appetite loss Yes No
 — Diarrhea Yes No
4. Social relations
 — Unchanged by the disease Yes No
 — Improved Yes No
 — Worsened Yes No




 — Depression Yes No
 — Insomnia Yes No
 — Poor concentration Yes No
 — Fatigue Yes No
 — Memory loss Yes No
 — Anxiety Yes No
 — Irritability Yes No
6. Osteoarticular pain
 — Joint pain Yes No
 — Bone pain Yes No
 — Muscle pain Yes No
7. Tiredness or vitality
 — Not lively Yes No
 — Agitated Yes No
 — Down in the dumps Yes No
 — No energy Yes No
 — Despondent Yes No
 — Exhausted Yes No
 — Unhappy Yes No
8. Specific symptoms
 — Kidney stone Yes No
 — Vomiting Yes No
 — Constipation Yes No
 — Tiredness Yes No
 — Itching Yes No
 — Sleepiness Yes No
